David Miklos, BSc, MD, PhD, Stanford University, Stanford, CA, discusses the outcomes of patients with large B-cell lymphoma who receive the chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel. Prof. Miklos gives an overview of the approval of axi-cel, based on data from the ZUMA-2 trial (NCT02601313), and highlights findings from a recent analysis of real-world data from 275 lymphoma patients who received axi-cel. Prof. Miklos reports that real-world data analysis validated results seen in clinical trials, with a complete response rate of 60%. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.